GEORGE S. EISENBARTH, M.D., Ph.D.
This content is PDF only. Please click on the PDF icon to access.
In most patients, type I diabetes results from autoimmune beta-cell destruction in the setting of a genetically determined predisposition (1). Approximately 95% of patients with type I diabetes express HLA antigens DR3 or DR4 or both (2), and within families, siblings with type I diabetes have in common at least one and often both HLA-haplotypes (3). In many patients, anti-islet antibodies precede overt diabetes. Several assays for anti-islet antibodies have been developed but the only assay that has shown prognostic significance measures binding of antibodies to non-fixed, frozen sections of normal human pancreas (4-8). Only a few research centers have
EISENBARTH GS. Immunotherapy of Type I Diabetes Mellitus. Ann Intern Med. 1985;102:846–848. doi: https://doi.org/10.7326/0003-4819-102-6-846
Download citation file:
Published: Ann Intern Med. 1985;102(6):846-848.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use